Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.
暂无分享,去创建一个
A. Levin | S. Henry | R. Yu | M. Templin | K. Denny
[1] E. Salewski,et al. Färbemethode zum makroskopischen Nachweis von Implantationsstellen am Uterus der Ratte , 1964, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.
[2] A. Levin,et al. Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. , 2004, Birth defects research. Part B, Developmental and reproductive toxicology.
[3] C. Teng,et al. Antisense Oligonucleotide-based Therapeutics , 2003 .
[4] B. Gazzard,et al. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. , 2002, American journal of ophthalmology.
[5] S. Crooke,et al. Antisense: Progress Towards Gene-Directed Cancer Therapy , 2002 .
[6] Rosie Yu,et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis , 2000, Nature Biotechnology.
[7] S. Agrawal,et al. Antisense therapeutics: is it as simple as complementary base recognition? , 2000, Molecular medicine today.
[8] S. Crooke,et al. Molecular mechanisms of action of antisense drugs. , 1999, Biochimica et biophysica acta.
[9] Lois E. H. Smith,et al. Oligonucleotide-based inhibition of embryonic gene expression , 1999, Nature Biotechnology.
[10] A. Levin,et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[11] W. Novotny,et al. Inhibition of coagulation by a phosphorothioate oligonucleotide. , 1997, Antisense & nucleic acid drug development.
[12] A. Levin,et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. , 1997, Antisense & nucleic acid drug development.
[13] P. Nicklin,et al. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. , 1997, Biochemical pharmacology.
[14] S. Crooke,et al. Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. , 1997, Anti-cancer drug design.
[15] D. Kornbrust,et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. , 1997, Toxicology.
[16] A. Krieg,et al. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. , 1996, Antisense & nucleic acid drug development.
[17] S. Agrawal,et al. Pharmacokinetics of Antisense Oligonucleotides , 1995, Clinical pharmacokinetics.
[18] V. Metelev,et al. Effect on embryos of injection of phosphorothioate-modified oligonucleotides into pregnant mice. , 1993, Antisense research and development.
[19] S. Beaucage,et al. Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach , 1992 .
[20] S. Agrawal,et al. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Haseman,et al. Selection of appropriate experimental units in teratology , 1974 .
[22] Staples Re,et al. REFINEMENTS IN RAPID CLEARING TECHNIC IN THE KOH-ALIZARIN RED S METHOD FOR FETAL BONE. , 1964 .